Albion News

Sunday Times Tech Track 100
Albion is thrilled to inform you that Quantexa will be featured on the 2020 Tech Track 100 in the Sunday Times today. Furthermore, they have been ranked at Number 14. This is a great achievement for Quantexa  and is a testament to everyone’s hard work, so a collective congratulations to everyone involved.   Through its pioneering platform, Quantexa helps organisations to maximise the value of data and transform decision making across the customer lifecycle, improving efficiency and maximising infrastructure investments. Since its inception in 2016, Quantexa has built a globally renowned... read more
Nadine Torbey - Top 50 UK Female tech investors
Every year, WoW (Women of Wearables) release a different Top Women list and this year they focussed on female investors in the UK tech space. Albion is delighted to see that our tech investment manager Nadine Torbey appears in the list for the first time. For the full story click here read more
Investment of the Year WINNER 2019 2.jpg
SEHTA announced the winners of our 2019 MedTech Business Awards and UCL Technology Fund investments Echopoint and ODIN won in two categories. Echopoint Medical won the Investment of the Year Award for their achievements in receiving equity investment from the UCL Technology Fund (managed by AlbionVC in partnership with UCLB) and Parkwalk Advisors as well as significant InnovateUK grants to develop their iKOr platform. ODIN Vision won the Start-Up of the Year Award as a leading start-up in a new era of artificial intelligence in endoscopy. Congratulations to all at Echopoint and ODIN.  To view... read more
Lancashire-based ELE provides highly specialised technology, including advanced robotics, to precision engineer components for the aerospace, power and automotive sectors for clients including GE, Rolls-Royce and Siemens. In its latest financial year, ELE generated revenues of almost £14 million, and currently employs more than 180 people from its facilities in Colne, Lancashire, and Trencin, Slovakia. Robert Whitby-Smith, Partner, Albion, says: “As a long-term supporter of ELE, we are delighted to have achieved a total return of 4x cost for our investors and that ELE has found a strong... read more
Hazy AI
Hazy -  has been listed by Forbes as one of the Top 15 European Machine Learning companies to watch. Hazy is an AI spin-out from UCL and is one of the businesses invested in by the UCLTechnology Fund which is managed by Albion in collaboration with UCLB. Hazy is a platform that helps businesses identify and anonymise personal data in large datasets whilst maintaining its utility, enabling Hazy’s customers to remain GDPR compliant. Hazy uses ML techniques to capture trends, patterns, and correlations in data in a single, compressed model, and then use this model to generate synthetic data that... read more
G Network
G.Network, Albion Capital and Cube IM are pleased to announce that G.Network and Albion have closed an agreement with Cube Infrastructure Fund II, whereby Cube II is providing an initial GBP60 million of additional funding to G.Network. G.Network is a fast-growing full fibre local access connectivity provider focused on London. G.Network is building and operating new Fibre to the Premises (FTTP) infrastructure across the capital to provide affordable ultra-fast fibre connectivity to businesses and residents. G.Network’s full fibre local access solutions are bridging the gap between old... read more
Dysis Imaging
DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors. In addition, Michael Gioffredi was appointed as Chief Commercial Officer. Former CEO Alastair Atkinson will remain with the company and assume the role of Chief Operating Officer. “We believe that Mr. Hammers and Mr. Gioffredi have the right leadership experience and knowledge of the U.S. medical device market to establish DYSIS as the leader in Colposcopy. On behalf of... read more
uMotif, the data capture company putting patients at the centre of clinical research, has raised £2.4 million in its latest funding round led by Albion Capital, the leading independent investment manager, along with several angel investors. uMotif’s software platform provides the patient-facing technology required to capture real-world data (eCOA, ePRo, eConsent) for the next generation of clinical research initiatives – from early phase to post-marketing trials. The technology is already in use by top pharma companies across Europe and North America, including AstraZeneca, Novartis and UCB... read more
Bloomsbury AI
The UCL Technology Fund is very proud to have backed BloomsburyAI and we are delighted that they are joining Facebook team in London.   For the full story please visit read more
DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra colposcope used in cervical cancer screening, announces today the completion of an £18 million ($25 million) investment. For the full story please click here read more